Symbol="YMAB"
AssetType="Common Stock"
Name="Y mAbs Therapeutics"
Description="Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of new antibody-based therapeutics for the treatment of cancer in the United States. The company is headquartered in New York, New York."
CIK="1722964"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="750 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="247216000"
EBITDA="-57817000"
PERatio="None"
PEGRatio="None"
BookValue="2.469"
DividendPerShare="0"
DividendYield="0"
EPS="-1.57"
RevenuePerShareTTM="1.717"
ProfitMargin="-0.985"
OperatingMarginTTM="-0.782"
ReturnOnAssetsTTM="-0.223"
ReturnOnEquityTTM="-0.557"
RevenueTTM="75032000"
GrossProfitTTM="57700000"
DilutedEPSTTM="-1.57"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.931"
AnalystTargetPrice="12.86"
TrailingPE="-"
ForwardPE="119.05"
PriceToSalesRatioTTM="5.21"
PriceToBookRatio="2.056"
EVToRevenue="2.523"
EVToEBITDA="-0.852"
Beta="0.678"
num_52WeekHigh="19.52"
num_52WeekLow="2.7"
num_50DayMovingAverage="7.14"
num_200DayMovingAverage="5.84"
SharesOutstanding="43677800"
DividendDate="None"
ExDividendDate="None"
symbol="YMAB"
open="5.64"
high="6.15"
low="5.57"
price="5.73"
volume="186583.00"
latest_trading_day="2023-08-08"
previous_close="5.66"
change="0.07"
change_percent="1.2367%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="16"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="84"
Volume_recent_avg="550691"
Change_recent_avg="-0.02"
Delta_recent_avg="0.53"
Variance_recent_avg="0.27"
Change_ratio_recent_avg="-0.26"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="84"
Aroon_momentum_negative="16"
image_negative_thumbnail_id_1="515"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0090.jpeg"
image_negative_thumbnail_id_2="1122"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0155.jpeg"
image_neutral_thumbnail_id_1="570"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_neutral_thumbnail_id_2="566"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_positive_thumbnail_id_1="680"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0028.jpeg"
image_positive_thumbnail_id_2="691"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0017.jpeg"
image_professor_thumbnail_id_1="1195"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
image_professor_thumbnail_id_2="1186"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
